Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond (Leukemia, (2018), 32, 2, (252-262), 10.1038/leu.2017.329)

C. S. Chim, Shaji K Kumar, R. Z. Orlowski, G. Cook, P. G. Richardson, Morie Gertz, S. Giralt, M. V. Mateos, X. Leleu, K. C. Anderson

Research output: Contribution to journalComment/debate

Abstract

Following the publication of this article the authors noted that the MRD data under the Table 1 column “Remark” of Aspire should go to that of Pollux. The authors wish to apologize for any inconvenience caused. The corrected table is attached to this correction.

Original languageEnglish (US)
Pages (from-to)1058-1059
Number of pages2
JournalLeukemia
Volume33
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Multiple Myeloma
Immunotherapy
Publications
Leukemia
Antibodies

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Correction : Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond (Leukemia, (2018), 32, 2, (252-262), 10.1038/leu.2017.329). / Chim, C. S.; Kumar, Shaji K; Orlowski, R. Z.; Cook, G.; Richardson, P. G.; Gertz, Morie; Giralt, S.; Mateos, M. V.; Leleu, X.; Anderson, K. C.

In: Leukemia, Vol. 33, No. 4, 01.04.2019, p. 1058-1059.

Research output: Contribution to journalComment/debate

Chim, C. S. ; Kumar, Shaji K ; Orlowski, R. Z. ; Cook, G. ; Richardson, P. G. ; Gertz, Morie ; Giralt, S. ; Mateos, M. V. ; Leleu, X. ; Anderson, K. C. / Correction : Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond (Leukemia, (2018), 32, 2, (252-262), 10.1038/leu.2017.329). In: Leukemia. 2019 ; Vol. 33, No. 4. pp. 1058-1059.
@article{78c349f1a41349189e8bbfaac2448603,
title = "Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond (Leukemia, (2018), 32, 2, (252-262), 10.1038/leu.2017.329)",
abstract = "Following the publication of this article the authors noted that the MRD data under the Table 1 column “Remark” of Aspire should go to that of Pollux. The authors wish to apologize for any inconvenience caused. The corrected table is attached to this correction.",
author = "Chim, {C. S.} and Kumar, {Shaji K} and Orlowski, {R. Z.} and G. Cook and Richardson, {P. G.} and Morie Gertz and S. Giralt and Mateos, {M. V.} and X. Leleu and Anderson, {K. C.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1038/s41375-019-0410-3",
language = "English (US)",
volume = "33",
pages = "1058--1059",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Correction

T2 - Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond (Leukemia, (2018), 32, 2, (252-262), 10.1038/leu.2017.329)

AU - Chim, C. S.

AU - Kumar, Shaji K

AU - Orlowski, R. Z.

AU - Cook, G.

AU - Richardson, P. G.

AU - Gertz, Morie

AU - Giralt, S.

AU - Mateos, M. V.

AU - Leleu, X.

AU - Anderson, K. C.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Following the publication of this article the authors noted that the MRD data under the Table 1 column “Remark” of Aspire should go to that of Pollux. The authors wish to apologize for any inconvenience caused. The corrected table is attached to this correction.

AB - Following the publication of this article the authors noted that the MRD data under the Table 1 column “Remark” of Aspire should go to that of Pollux. The authors wish to apologize for any inconvenience caused. The corrected table is attached to this correction.

UR - http://www.scopus.com/inward/record.url?scp=85062627472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062627472&partnerID=8YFLogxK

U2 - 10.1038/s41375-019-0410-3

DO - 10.1038/s41375-019-0410-3

M3 - Comment/debate

C2 - 30842604

AN - SCOPUS:85062627472

VL - 33

SP - 1058

EP - 1059

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 4

ER -